N4 Pharma plc (N4P) ORD GBP0.004
- Add to watchlist
- Create an alert
- This stock can be held in a
Business summary
N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.
Contact details
Important dates
General stock information
- EPIC:
- N4P
- ISIN:
- GB00BYW8QM32
- Market cap:
- £2.57 million
- Shares in issue:
- 394.78 million
- Sector:
- Software & Computer Services
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.